RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

Subbiah, V., Sahai, V., Maglic, D., Bruderek, K., Touré, B. B., Zhao, S., Valverde, R., O’Hearn, P. J., Moustakas, D. T., Schönherr, H., Gerami-Moayed, N., Taylor, A. M., Hudson, B. M., Houde, D. J., Pal, D., Foster, L., Gunaydin, H., Ayaz, P., Sharon, D. A., … Casaletto, J. B. (2023). RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations. Cancer Discovery, 13(9), 2012–2031. https://doi.org/10.1158/2159-8290.cd-23-0475
Authors:
Vivek Subbiah
Vaibhav Sahai
Dejan Maglic
Kamil Bruderek
B Barry Touré
Songping Zhao
Roberto Valverde
Patrick J O'Hearn
Demetri T Moustakas
Heike Schönherr
Nastaran Gerami-Moayed
Alexander M Taylor
Brandi M Hudson
Damian J Houde
Debjani Pal
Lindsey Foster
Hakan Gunaydin
Pelin Ayaz
Dina A Sharon
Lipika Goyal
Alison M Schram
Suneel Kamath
Cori Ann Sherwin
Oleg Schmidt-Kittler
Kai Yu Jen
Fabien Ricard
Beni B Wolf
David E Shaw
Donald A Bergstrom
James Watters
Jessica B Casaletto
Affiliated Authors:
David E Shaw
Columbia Affiliation:
Subjects:
Cholangiocarcinoma (MeSH)
Bile Duct Neoplasms (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1158/2159-8290.cd-23-0475
PMID:
37270847
DOI:
10.1158/2159-8290.cd-23-0475
Journal:
Cancer Discovery
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record

Record Created: